TickerFacts.

Company research / AMGN

Amgen Inc (AMGN)

Build a valuation ↗↓ Download CSV

SEC name AMGEN INC · CIK 0000318154 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Amgen Inc reported revenue of $36.75B. Revenue grew 10.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $38.09B.

Key ratios (year ended 2025-12-31)

67.2%
Gross margin (computed)
24.7%
Operating margin
21.0%
Net margin
89.1%
Return on year-end equity
10.0%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-08-13

Headquarters locality: Thousand Oaks · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$38.09B$36.75B$33.42B$28.19B$26.32B$25.98B$25.42B$23.36B$23.75B$22.85B$22.99B
Cost of Revenue$11.61B$12.04B$12.86B$8.45B$6.41B$6.45B$6.16B$4.36B$4.10B$4.07B$4.16B
Gross Profit (computed)$26.48B$24.71B$20.57B$19.74B$19.92B$19.52B$19.27B$19.01B$19.65B$18.78B$18.83B
R&D Expense$7.63B$7.27B$5.96B$4.78B$4.43B$4.82B$4.21B$4.12B$3.74B$3.56B$3.84B
Operating Income$11.43B$9.08B$7.26B$7.90B$9.57B$7.64B$9.14B$9.67B$10.26B$9.97B$9.79B
Depreciation & Amortization$4.67B$5.17B$5.59B$4.07B$3.42B$3.40B$3.60B$2.21B$1.95B$1.96B$2.10B
EBITDA$16.09B$14.25B$12.85B$11.97B$12.98B$11.04B$12.74B$11.88B$12.21B$11.93B$11.90B
Net Income$8.74B$7.71B$4.09B$6.72B$6.55B$5.89B$7.26B$7.84B$8.39B$1.98B$7.72B
EPS (Diluted)n/a$14.23$7.56$12.49$12.11$10.28$12.31$12.88$12.62$2.69$10.24
Total Assets$95.64B$90.59B$91.84B$97.15B$65.12B$61.16B$62.95B$59.71B$66.42B$79.95B$77.63B
Long-Term Debt$57.30B$54.60B$60.10B$64.61B$38.95B$33.31B$32.99B$29.90B$33.93B$35.34B$34.60B
Shareholders' Equity$11.69B$8.66B$5.88B$6.23B$3.66B$6.70B$9.41B$9.67B$12.50B$25.24B$29.88B
Cash & Equivalents$13.99B$9.13B$11.97B$10.94B$7.63B$7.99B$6.27B$6.04B$6.95B$3.80B$3.24B
Operating Cash Flow$12.48B$9.96B$11.49B$8.47B$9.72B$9.26B$10.50B$9.15B$11.30B$11.18B$10.35B
Capital Expenditures$2.30B$1.86B$1.10B$1.11B$936.00M$880.00M$608.00M$618.00M$738.00M$664.00M$738.00M
Free Cash Flow$10.18B$8.10B$10.39B$7.36B$8.79B$8.38B$9.89B$8.53B$10.56B$10.51B$9.62B
Share Repurchasesn/a$0$200.00M$0$6.36B$4.97B$3.49B$7.70B$17.79B$3.16B$2.96B
Dividends Paid$5.29B$5.12B$4.83B$4.56B$4.20B$4.01B$3.75B$3.51B$3.51B$3.37B$3.00B
Shares Outstanding540.60M538.80M536.90M535.40M534.00M558.30M578.30M591.40M629.60M722.20M738.20M
Dividends Per Sharen/a$9.66$9.13$8.64$7.95$7.22$6.56$5.95$5.41$4.77$4.15
Weighted Average Diluted Sharesn/a542.00M541.00M538.00M541.00M573.00M590.00M609.00M665.00M735.00M754.00M
EPS (Basic)n/a$14.33$7.62$12.56$12.18$10.34$12.40$12.96$12.70$2.71$10.32

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView